Levodopa–Entacapone–Carbidopa Intestinal Gel in advanced Parkinson’s disease: clinical positioning, candidate profiling, and implementation roadmap
Device-aided therapies (DATs) for Parkinson’s disease (PD) with motor complications encompass deep brain stimulation (DBS), intrajejunal and subcutaneous infusions. Levodopa-carbidopa-entacapone intestinal gel (LECIG) infusion is the most recent strategy to be included in the intrajejunal class. By adding peripheral catechol-O-methyltransferase (COMT) inhibition, LECIG increases levodopa bioavailability, enabling a comparable dopaminergic effect at a reduced levodopa dose and infusion volume. Drawing on the discussion of a national advisory board of Italian movement disorder specialists, this perspective addresses the positioning of LECIG in PD patients with motor fluctuations. LECIG broadens the intrajejunal infusion landscape with a smaller device and potential metabolic advantages related to reduced 3-O-methyldopa generation. Two candidate scenarios predominate: the patient requiring a first infusional DAT after failure of optimized oral therapy who is ineligible for or declines DBS, and the patient already on a DAT with residual or worsening/re-emergent fluctuations. Favorable selection features include a levodopa-responsive, motor-fluctuation-predominant phenotype, documented COMT-inhibitor tolerance, absence of overt dementia with adequate caregiver support, a rationale for levodopa dose sparing (e.g., peripheral neuropathy risk), and concomitant dysphagia that features an additional niche benefitting of intestinal therapies. Cautionary or unfavorable features include levodopa-resistant axial disability, severe cognitive impairment, absence of caregiver support, COMT-inhibitor intolerance, and active neuropsychiatric symptoms, other than gastrointestinal contraindication for receiving gastrojejunostomy. Implementation barriers include the need for structured gastroenterology collaboration, and a potential cost-per-quality-adjusted-life-year higher than comparator DATs. Precise, multidimensional patient selection, together with a prescribing roadmap, with prospective registries, and structured multidisciplinary agenda, could be the cornerstone of optimizing outcomes.
Authors
- Giulia Lazzeri (ORCID: https://orcid.org/0000-0002-9912-2002)
- Francesco Cavallieri (ORCID: https://orcid.org/0000-0001-5836-1982)
- Daniele Belvisi (ORCID: https://orcid.org/0000-0001-8681-3050)
- Massimo Marano (ORCID: https://orcid.org/0000-0001-9885-3666)
- Valentina Leta (ORCID: https://orcid.org/0000-0002-5794-7540)
- Mario Meloni (ORCID: https://orcid.org/0000-0002-6319-3458)
- Edoardo Bianchini (ORCID: https://orcid.org/0000-0001-7955-3369)
- Pierluigi Tocco
- Maria Chiara Malaguti (ORCID: https://orcid.org/0000-0002-4807-4063)
- Carlo Alberto Artusi (ORCID: https://orcid.org/0000-0001-8579-3772)
- Chiara Sorbera (ORCID: https://orcid.org/0000-0002-5872-3119)
- Micol Avenali (ORCID: https://orcid.org/0000-0002-7880-9921)
- Rosa De Micco
Institutions
- Institut polytechnique de Grenoble (FR)
- University of Verona (IT)
- Centre National de la Recherche Scientifique (FR)
- Università Campus Bio-Medico (IT)
- King's College London (GB)
- University of Campania "Luigi Vanvitelli" (IT)
- University of Pavia (IT)
- Istituto Neurologico Mediterraneo (IT)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- Laboratoire d'Informatique de Grenoble (FR)
- Provincia Autonoma di Trento (IT)
- Azienda Ospedaliero-Universitaria Cagliari (IT)
- Campus Bio Medico University Hospital (IT)
- Azienda USL di Pescara (IT)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Parkinson's Institute and Clinical Center (US)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3389/fneur.2026.2017429
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00